Genzyme Corporation Angers Patients Over Fabrazyme Supplies

What consent decree? Just one week after sending a July 26 letter to patients that limited allocations of the Fabrazyme medication would remain available this month, Genzyme is now telling patients that unspecified quality control problems have disrupted supplies. Although the disruption is supposed to be brief, Genzyme was unable to say when Fabrazyme would be shipped, according to patients. “I got a call from my nurse case manager (at Genzyme) to say there’s no drug available this month,” Tom Olshewski of Grayling, Michigan, tells us. “I was told there’ll be no medicine until further notice.” And Michael Masula of Kilbuck, Pennsylvania says that “it was due to a quality control issue and they anticipate it being short lived…but they always say it’s going to be short lived” (read about Masula here). The latest snafu is also discussed on patient chat boards, such as this one.

Back to news